300
Participants
Start Date
July 30, 2024
Primary Completion Date
June 30, 2026
Study Completion Date
June 30, 2026
Ofatumumab
This is an observational study. There is no treatment allocation. The decision to initiate treatment with ofatumumab (Kesimpta®) will be based solely on clinical judgement and according to the SmPC and AIFA reimbursement criteria.
RECRUITING
Novartis Investigative Site, Orbassano
RECRUITING
Novartis Investigative Site, Torino
RECRUITING
Novartis Investigative Site, Genova
RECRUITING
Novartis Investigative Site, Monza
RECRUITING
Novartis Investigative Site, Gallarate
RECRUITING
Novartis Investigative Site, Bergamo
RECRUITING
Novartis Investigative Site, Pavia
RECRUITING
Novartis Investigative Site, Novara
RECRUITING
Novartis Investigative Site, Vicenza
RECRUITING
Novartis Investigative Site, Trento
RECRUITING
Novartis Investigative Site, Cona
RECRUITING
Novartis Investigative Site, Ravenna
RECRUITING
Novartis Investigative Site, Florence
RECRUITING
Novartis Investigative Site, Ancona
RECRUITING
Novartis Investigative Site, Chieti
RECRUITING
Novartis Investigative Site, L’Aquila
RECRUITING
Novartis Investigative Site, Bari
RECRUITING
Novartis Investigative Site, Foggia
RECRUITING
Novartis Investigative Site, Napoli
RECRUITING
Novartis Investigative Site, Napoli
RECRUITING
Novartis Investigative Site, Pozzilli
RECRUITING
Novartis Investigative Site, Catanzaro
RECRUITING
Novartis Investigative Site, Reggio Calabria
RECRUITING
Novartis Investigative Site, Palermo
RECRUITING
Novartis Investigative Site, Roma
RECRUITING
Novartis Investigative Site, Roma
RECRUITING
Novartis Investigative Site, Sassari
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY